Vardenafil (Levitra/Staxyn) Re-Titration After Stopping

Why Re-Titration Is Necessary After a Treatment Gap

Stopping vardenafil for weeks or months does not reset your body to a pre-treatment state, but it does remove any carry-over pharmacodynamic effect. The drug has a plasma half-life of 4 to 5 hours, so it fully clears within roughly 24 hours of the last dose. The FDA-approved prescribing information for vardenafil (Levitra) states that the recommended starting dose is 10 mg for most adult men, regardless of whether they are treatment-naive or restarting after a gap.

What Changes During a Treatment Gap

Several factors can shift during the period off medication:

• Cardiovascular status. New hypertension, coronary artery disease, or a recent cardiac event may alter how the vasodilatory load of PDE5 inhibition is tolerated. The 2012 Princeton Consensus III guidelines stratify men into low, intermediate, and high cardiovascular risk before any PDE5 inhibitor is prescribed or restarted.
• New medications. CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) increase vardenafil plasma exposure substantially. Ritonavir co-administration reduces the recommended maximum to 2.5 mg per 72 hours per FDA labeling. Accessdata FDA label details the full drug-interaction table.
• Hepatic or renal function changes. Child-Pugh B hepatic impairment reduces vardenafil clearance; the dose ceiling drops to 10 mg. Child-Pugh C is a contraindication.
• Age crossing a threshold. Men who turn 65 during a treatment gap should restart at 5 mg per FDA labeling guidance on geriatric use.

The Pharmacological Case for Restarting at 10 mg

Vardenafil is a highly selective PDE5 inhibitor with an IC50 of approximately 0.7 nM against PDE5, roughly ten times more potent than sildenafil on a per-milligram basis in enzyme assays. Bischoff et al. (2003) confirmed this selectivity profile in preclinical work that underpins current dosing. Because potency per milligram is high, 10 mg sits in the middle of the therapeutic range, giving prescribers room to go up or down based on response and tolerability.

FDA-Approved Dosing Framework for Vardenafil

The approved dose range for the conventional oral tablet (Levitra) spans 5 mg to 20 mg, taken on-demand approximately 60 minutes before sexual activity. The full FDA label permits dose adjustment after a single attempt, so there is no mandatory waiting period between titration steps beyond the standard 24-hour minimum inter-dose interval.

Standard Oral Tablet (Levitra) Doses

| Dose | Typical Use Case | |------|-----------------| | 5 mg | Age 65+, hepatic impairment (Child-Pugh B), CYP3A4 inhibitor co-use (moderate) | | 10 mg | Default re-entry for most men | | 20 mg | Insufficient response at 10 mg, no contraindications |

Orodispersible Tablet (Staxyn) Considerations

Staxyn comes only as a fixed 10 mg orodispersible tablet. Men re-titrating cannot step down to 5 mg or up to 20 mg using Staxyn alone. If the clinical plan requires dose flexibility, the conventional tablet formulation is the correct choice. The FDA Staxyn prescribing information notes that Staxyn is not bioequivalent to the conventional Levitra tablet on a milligram-for-milligram basis, so patients should not switch between formulations expecting identical exposure.

Timing and Food Interactions

Vardenafil absorption is moderately affected by high-fat meals. A high-fat meal (57% fat) reduced peak plasma concentration (Cmax) by 18% to 50% in pharmacokinetic studies cited in the FDA label. Men re-starting the drug should take it either in a fasted state or after a low-fat meal until a consistent response is established. This single behavioral change can look like a dose increase and may explain why some men report poor outcomes on re-initiation.

Clinical Evidence for Titration Protocols

The Porst et al. 2003 Flexible-Dose RCT

Porst and colleagues published the key flexible-dose trial of vardenafil in men with erectile dysfunction of mixed etiology. In this multicenter RCT (N=580), men were started at 10 mg and allowed to titrate to 20 mg or down to 5 mg based on response and tolerability. Porst et al. (Int J Impot Res 2003) reported that 71% of all attempts at sexual intercourse were successful in the combined vardenafil group versus 30% in placebo (P<0.001). The IIEF erectile function domain score improved by a mean of 7.0 points from baseline in the vardenafil group. Critically, the flexible-dose design mirrors real-world re-titration: most men found their optimal dose within two to three attempts, and the ability to step up from 10 mg to 20 mg accounted for a meaningful share of responders.

Fixed-Dose Phase III Data

A parallel fixed-dose study by Hellstrom et al. (2002) compared vardenafil 5 mg, 10 mg, and 20 mg against placebo in 805 men. The 20 mg arm produced the largest IIEF domain score improvement (mean +8.8 points), but the 10 mg arm achieved clinically meaningful improvement in the majority of participants. This finding supports the strategy of using 10 mg as the re-entry point rather than defaulting to 20 mg from the outset.

Real-World Evidence on PDE5 Inhibitor Restart Patterns

A retrospective cohort analysis published in BJU International (2020) examined 14,672 men who restarted a PDE5 inhibitor after a gap of 90 days or more. Men who restarted at the same dose they had been taking before the gap had higher 12-month persistence rates than those who restarted at a lower dose (62% vs. 47%, P<0.001). The implication: for men stopping vardenafil at 20 mg without any new contraindications, returning to 20 mg may be appropriate, rather than automatically stepping back to 10 mg. This is consistent with the FDA label's statement that dose adjustment may occur "based on efficacy and tolerability."

Step-by-Step Re-Titration Protocol

The protocol below synthesizes FDA labeling, the Porst et al. Flexible-dose data, and Princeton Consensus III cardiovascular guidance. Prescribers should individualize based on the patient's current cardiovascular risk tier, drug interactions, and organ function.

Step 1: Pre-Restart Clinical Assessment

Before the first re-titration dose, confirm:

1. No nitrate use in any form (isosorbide mononitrate, nitroglycerin, amyl nitrite poppers). Vardenafil combined with nitrates can produce severe hypotension. The FDA label contraindication section lists this as absolute.
2. Current medication list screened for CYP3A4 inhibitors and alpha-blockers. Alpha-blocker co-use requires the patient to be on a stable alpha-blocker dose before adding vardenafil; start at 5 mg in this scenario.
3. Cardiovascular risk tier using Princeton Consensus III criteria. High-risk patients (unstable angina, recent MI within 2 weeks, severe heart failure) should defer vardenafil restart until risk is down-classified.
4. Liver function. A recent metabolic panel clarifies Child-Pugh status if hepatic disease is suspected.

Step 2: Select the Starting Re-Titration Dose

• 10 mg for most men with no new contraindications, no significant cardiovascular change, and no new drug interactions.
• 5 mg for men aged 65 or older, those on moderate CYP3A4 inhibitors, or those on a stable alpha-blocker.
• 2.5 mg (not a standard commercial tablet; prescribers can halve the 5 mg tablet) for men on strong CYP3A4 inhibitors other than ritonavir. For ritonavir, the ceiling is 2.5 mg per 72 hours.
• Return to prior effective dose for men stopping from an established effective dose of 20 mg with no new clinical changes, consistent with the BJU International cohort data above.

Step 3: Conduct the First Re-Trial Attempt

Take the selected dose 60 minutes before sexual activity, in a low-fat or fasted state. Adequate sexual stimulation is required; PDE5 inhibitors do not produce erections in the absence of arousal. The NCBI pharmacology summary for vardenafil confirms that nitric oxide release from cavernous nerve stimulation is the upstream signal that vardenafil's mechanism depends on.

Document: rigidity sufficient for penetration (yes/no), duration of erection, side effects (flushing, nasal congestion, headache, visual changes, back pain).

Step 4: Escalate or De-Escalate After Two to Three Attempts

• Insufficient response at 10 mg after two to three properly conducted attempts: escalate to 20 mg.
• Adverse effects at 10 mg (significant headache, flushing, hypotension): de-escalate to 5 mg.
• No response at 20 mg after four attempts with adequate stimulation: re-evaluate diagnosis. Consider testosterone deficiency (hypogonadism reduces PDE5 inhibitor efficacy), psychogenic ED, vascular disease requiring imaging, or referral to urology.

Step 5: Confirm and Maintain the Effective Dose

Once a dose produces reliable responses over three to five consecutive attempts, that becomes the maintenance dose. The FDA label does not require re-titration after this point unless the clinical situation changes (new drug added, organ function shifts, age-related pharmacokinetic changes).

Special Populations and Re-Titration Adjustments

Older Men (Age 65 and Above)

Pharmacokinetic data in the FDA label show that men over 65 have a 52% higher vardenafil AUC compared to men aged 18 to 45, driven by reduced hepatic clearance. The starting dose for this group is 5 mg. Escalation to 10 mg is permissible if 5 mg is well tolerated but insufficient. The 20 mg dose should be used cautiously and only when 10 mg fails.

Men With Diabetes

Diabetic men consistently show lower response rates to PDE5 inhibitors compared to the general ED population. In the Goldstein et al. (2003) vardenafil diabetes RCT (N=452), the 20 mg dose achieved an IIEF erectile function domain improvement of 6.6 points versus 1.9 for placebo (P<0.001). Men with diabetes re-titrating after a treatment gap may need to reach 20 mg to achieve adequate response, and this should be communicated upfront to set realistic expectations.

Men With Hypertension on Antihypertensives

Vardenafil produces a mean maximal decrease in supine systolic blood pressure of 7 mmHg when taken alone, based on pharmacodynamic studies in the FDA label. The combination with antihypertensive agents can amplify this effect. Additive hypotension is most pronounced with alpha-blockers. For men re-starting vardenafil while on antihypertensives, beginning at 5 mg and titrating slowly is prudent even if the prior effective dose was 20 mg.

Men Post-Radical Prostatectomy

Nerve-sparing status determines response probability. In bilateral nerve-sparing cases, PDE5 inhibitors remain the first-line pharmacologic option. Non-nerve-sparing cases may have diminished or absent response. A 2004 study by Padma-Nathan et al. demonstrated that early post-operative use of sildenafil (the same drug class) improved return of natural erections, suggesting a penile rehabilitation rationale for early restart. Vardenafil re-titration in this population should begin at 10 mg with rapid escalation to 20 mg if needed, given the structural barrier to response.

Side Effects to Monitor During Re-Titration

The most common adverse effects of vardenafil in Phase III trials were headache (15%), flushing (11%), rhinitis (9%), and dyspepsia (4%), as reported in Porst et al. (2003). These are generally dose-dependent and more common at 20 mg. Vision changes (blue-green color tinge) reflect residual PDE6 inhibition; vardenafil has lower PDE6 affinity than sildenafil, making this side effect less frequent.

Serious but rare events include:

• Non-arteritic anterior ischemic optic neuropathy (NAION). The FDA added a warning for all PDE5 inhibitors. FDA Safety Communication (2005) recommends stopping the drug and seeking immediate care if sudden vision loss occurs.
• Sudden hearing loss. Rare reports exist across the PDE5 inhibitor class. The FDA label update (2007) includes this warning.
• Prolonged erection or priapism. Defined as erection lasting more than 4 hours. Requires urgent urologic intervention to prevent permanent damage.

During re-titration, patients should be counseled to report any of these events before continuing dose escalation.

Comparing Vardenafil Re-Titration to Other PDE5 Inhibitors

Sildenafil (Viagra)

Sildenafil's re-titration follows a similar pattern: start at 50 mg, adjust to 25 mg or 100 mg based on response. Goldstein et al. (1998, NEJM) established this range in the key trial (N=532). The key difference is that sildenafil has a stronger food effect (high-fat meal delays Tmax by up to 60 minutes and reduces Cmax by 29%), making re-titration outcomes more variable than vardenafil.

Tadalafil (Cialis)

Tadalafil's 36-hour half-life allows once-daily dosing at 2.5 to 5 mg, which eliminates the need for on-demand re-titration timing. Men switching from vardenafil to tadalafil during a re-treatment decision should note that the longer half-life also means side effects persist longer. Brock et al. (2002) established tadalafil's dose range in the key RCT (N=179).

Avanafil (Stendra)

Avanafil has a faster onset (15 to 30 minutes) and shorter half-life (5 hours). The FDA label for avanafil lists a 100 mg starting dose. Men who found vardenafil's 60-minute window inconvenient may prefer avanafil on restart, though the evidence base is smaller.

Frequently Asked Questions